Full-Time

Executive Director

Commercial Strategy & Planning

Posted on 11/18/2024

Syndax

Syndax

201-500 employees

Develops cancer therapies and conducts clinical trials

Biotechnology
Healthcare

Senior, Expert

Waltham, MA, USA

Category
Business Research
Strategy Development
Business & Strategy
Required Skills
Market Research
Requirements
  • Bachelor’s degree in Business, Marketing, or Life Sciences required.
  • MBA or advanced degree in a related field preferred.
  • Minimum 15 years of progressive experience in biopharmaceutical commercialization.
  • Minimum of 7 years experience leading strategic initiatives within commercial functions.
  • Oncology experience required; hematology experience preferred.
  • Proven track record in leading strategic commercialization in the U.S. and ex U.S. markets.
  • Experience as part of a cross-functional program team supporting early- and late-stage programs through regulatory milestones (NDA/BLA), life cycle management and geographical expansion.
  • Extensive experience in leading product launches and lifecycle management.
  • Strong understanding of the oncology/hematology market landscape, including regulatory requirements, payer dynamics, and competitor positioning.
  • Superior strategic thinking, data-driven decision-making, and analytical skills.
  • Excellent communication and leadership abilities, with the capability to influence cross-functional teams and senior leadership.
  • Ability to navigate and thrive in a fast-paced, highly dynamic environment.
Responsibilities
  • A key leader of the Asset Strategy Team, member of the Customer Engagement Leadership Team, and representative of the Syndax commercial team across the US and key international markets, responsible for providing commercial input into the Integrated Strategic Plan for strategic assets.
  • Key contributor in the development of the Menin portfolio strategy and lifecycle activities including indication sequencing and prioritization.
  • Commercial lead for development and implementation of integrated strategic plans, aligning short- mid- and long-term goals across the organization.
  • Support the creation of development plans that achieve a unique value proposition to ensure competitive differentiation in target markets.
  • Consider patient-centric commercialization strategies by understanding patient journeys and applying insights into actionable strategies.
  • Lead commercialization strategies for pipeline assets, from clinical development through commercialization.
  • Identify and analyze market trends, competitor activities, and emerging therapies to refine pipeline marketing efforts.
  • Partner with R&D, clinical, medical, and commercial teams to incorporate market feedback and ensure alignment of pipeline programs with market needs.
  • Drive asset-specific marketing strategies to maximize product value and market potential.
  • Develop and implement lifecycle management plans for each asset, including indication expansion, positioning shifts, and competitive readiness.
  • Utilize data-driven insights and market research to assess potential asset opportunities and challenges, informing asset prioritization and resource allocation.
  • Collaborate with medical affairs, HEOR, and market access teams to optimize asset strategies that synthesize and address payer, provider, and patient needs.
  • Lead the development of launch strategies for new products, including market entry strategies, pricing, and reimbursement planning.
  • Conduct in-depth market assessments and revenue forecasts for new product candidates to guide strategic decision-making.
  • Established relationships with key opinion leaders (KOLs), academic/community centers, advocacy groups, and stakeholders to gather insights and inform new and established product planning.
  • Ensure that commercial strategies for new products align with Syndax’s broader portfolio strategy and meet regulatory requirements.
  • Lead by influence and demonstrate collaborative behaviors to foster cross-functional way of working, both with the teams and with the functions.

Syndax Pharmaceuticals develops and commercializes therapies specifically for cancer patients, focusing on challenging cases like hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The company conducts research and clinical trials to test the safety and effectiveness of its drugs, aiming to bring them to market after receiving regulatory approval. Syndax's main product, Entinostat, is currently in clinical trials combined with Exemestane for treating HR+, HER2- breast cancer. Unlike many competitors, Syndax targets underserved patient populations and relies on strategic partnerships and public offerings to fund its research and development. The goal is to advance cancer treatment by developing new therapies that address the needs of patients with difficult-to-treat cancers.

Company Stage

IPO

Total Funding

$144.3M

Headquarters

Waltham, Massachusetts

Founded

2005

Growth & Insights
Headcount

6 month growth

30%

1 year growth

51%

2 year growth

154%
Simplify Jobs

Simplify's Take

What believers are saying

  • Positive clinical trial results for revumenib in combination therapies suggest strong potential for regulatory approval and market success.
  • The appointment of experienced professionals like Aleksandra Rizo to the board of directors enhances the company's strategic direction and clinical development capabilities.
  • Syndax's inducement grants and stock options for new employees indicate a commitment to attracting and retaining top talent, fostering a culture of innovation.

What critics are saying

  • The highly competitive oncology market requires continuous innovation and successful clinical trials to maintain a competitive edge.
  • Dependence on the success of key products like Entinostat and revumenib means that any setbacks in clinical trials or regulatory approvals could significantly impact the company's growth.

What makes Syndax unique

  • Syndax focuses on developing therapies for difficult-to-treat cancers, particularly HR+, HER2- breast cancer, setting it apart from competitors with broader oncology portfolios.
  • The company's flagship product, Entinostat, and its innovative pipeline, including revumenib and axatilimab, highlight its commitment to targeting specific cancer pathways and patient populations.
  • Syndax's strategic capital raises and public offerings provide robust financial support for its R&D efforts, unlike competitors who may struggle with funding.

Help us improve and share your feedback! Did you find this helpful?